Literature DB >> 16829051

Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections.

Teresita Mazzei1, Maria Iris Cassetta, Stefania Fallani, Silvia Arrigucci, Andrea Novelli.   

Abstract

Uncomplicated urinary tract infections (UTI) are treated with beta-lactams, co-trimoxazole, quinolones and fosfomycin tromethamine. Due to increasing resistance of causative pathogens, antibiotics should be used by considering their pharmacodynamic and pharmacokinetic characteristics. beta-lactams have time-dependent activity and should not be used once-daily. Co-trimoxazole should be restricted due to increasing chemoresistance. Fluoroquinolones play a primary role in the treatment of serious and complicated infections. Fosfomycin tromethamine is active against most urinary tract pathogens. In vitro time-kill kinetics of fosfomycin against Escherichia coli and Proteus mirabilis showed primarily concentration-dependent activity, with a prolonged post-antibiotic effect (3.4 to 4.7h). Based on these results a single 3g dose of fosfomycin guarantees optimal efficacy against common uropathogens with an AUC(urine)/MIC ratio of 500.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829051     DOI: 10.1016/j.ijantimicag.2006.05.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  19 in total

Review 1.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

Review 3.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 4.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

5.  In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates.

Authors:  Christoph Hauser; Lea Hirzberger; Magnus Unemo; Hansjakob Furrer; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

Review 6.  The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

7.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

8.  Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Authors:  Angela Huttner; Anna Kowalczyk; Adi Turjeman; Tanya Babich; Caroline Brossier; Noa Eliakim-Raz; Katarzyna Kosiek; Begoña Martinez de Tejada; Xavier Roux; Shachaf Shiber; Ursula Theuretzbacher; Elodie von Dach; Dafna Yahav; Leonard Leibovici; Maciek Godycki-Cwirko; Johan W Mouton; Stephan Harbarth
Journal:  JAMA       Date:  2018-05-01       Impact factor: 56.272

Review 9.  Fosfomycin: Uses and potentialities in veterinary medicine.

Authors:  D S Pérez; M O Tapia; A L Soraci
Journal:  Open Vet J       Date:  2014-03-16

10.  Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

Authors:  Sander G Kuiper; Anneke C Dijkmans; Erik B Wilms; Ingrid M C Kamerling; Jacobus Burggraaf; Jasper Stevens; Cees van Nieuwkoop
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.